Introduction: Rates of drug use in Nigeria are among the highest globally, with the use of opioids associated with increased morbidity and mortality, more so with injecting drug use (IDU). Medication-assisted treatment (MAT) can reduce risks, and with a country-specific guideline in place, plans for country-wide implementation of MAT are underway. A notable barrier to MAT uptake is professionals’ knowledge and attitudes. Aim: This study aimed to evidence the opinions of treatment and prevention substance use (SUD) professionals in Nigeria regarding MAT. Method: An online Google form was developed by the researchers to assess knowledge and attitudes towards MAT. This form was circulated among substance use professionals across the six geopolitical zones and the capital territory in Nigeria. Three hundred and thirty-eight professionals completed the questionnaire. Results: Most were medical doctors (53.8%) and worked in the public sector (89%). Average work experience was 11 years, and respondents estimated that nearly 1 in 10 Opioid use disorder (OUD) patients they cared for were IDUs. A majority (85.7%) endorsed the need for MAT in Nigeria, though had no previous experience (65.3%), training (74.2%), or knowledge of existing guidelines (68.7%). Over half (55%) endorsed a preference for buprenorphine and methadone to be made available. Conclusion: Most endorsed positive attitudes towards MAT and its rollout. SUD professionals endorsed positive attitudes towards MAT for OUDs and its rollout in Nigeria. Awareness of published guidelines and training are unmet needs arising from this study.
References
[1]
Osayomi, T., Iyanda, A.E., Adeleke, R. and Osadolor, O.J. (2021) Geographical Analysis of Illicit Drug Use in Nigeria: Evidence from the First National Drug Use Survey, 2018. TheProfessionalGeographer, 73, 377-391. https://doi.org/10.1080/00330124.2021.1883445
[2]
Ifeadi, C.N. and Agodi, F. (2024) Misuse and Abuse of Prescription Drugs: An Overview. In: Disseminating Sch Res across Globe, International Institute for African Scholars. Fayetteville, 27-57.
[3]
Emmanuel, G.O., Akinsolu, F.T., Abodunrin, O.R. and Ezechi, O.C. (2024) Prevalence and Patterns of Substance Use in West Africa: A Systematic Review and Meta-Analysis. PLOS Global Public Health, 4, e0004019. https://doi.org/10.1371/journal.pgph.0004019
[4]
Moore, K.E., Siebert, S.L., Kromash, R., Owens, M.D. and Allen, D.C. (2022) Negative Attitudes about Medications for Opioid Use Disorder among Criminal Legal Staff. Drug and Alcohol Dependence Reports, 3, Article 100056. https://doi.org/10.1016/j.dadr.2022.100056
[5]
Kruis, N.E., McLean, K. and Perry, P. (2021) Exploring First Responders’ Perceptions of Medication for Addiction Treatment: Does Stigma Influence Attitudes? Journal of Substance Abuse Treatment, 131, Article 108485. https://doi.org/10.1016/j.jsat.2021.108485
[6]
Majer, J.M., Beasley, C., Stecker, E., Bobak, T.J., Norris, J., Nguyen, H.M., et al. (2018) Oxford House Residents’ Attitudes toward Medication Assisted Treatment Use in Fellow Residents. Community Mental Health Journal, 54, 571-577. https://doi.org/10.1007/s10597-017-0218-4
[7]
Matusow, H., Dickman, S.L., Rich, J.D., Fong, C., Dumont, D.M., Hardin, C., et al. (2013) Medication Assisted Treatment in US Drug Courts: Results from a Nationwide Survey of Availability, Barriers and Attitudes. Journal of Substance Abuse Treatment, 44, 473-480. https://doi.org/10.1016/j.jsat.2012.10.004
[8]
UNODC (2022) Medication-Assisted Treatment for Opioid Dependence in Nigeria: Methadone and Buprenorphine.
[9]
Odejide, A.O. (2006) Status of Drug Use/Abuse in Africa: A Review. InternationalJournalofMentalHealthandAddiction, 4, 87-102. https://doi.org/10.1007/s11469-006-9015-y
[10]
Petersen, I., Marais, D., Abdulmalik, J., Ahuja, S., Alem, A., Chisholm, D., et al. (2017) Strengthening Mental Health System Governance in Six Low-and Middle-Income Countries in Africa and South Asia: Challenges, Needs and Potential Strategies. HealthPolicyandPlanning, 32, 699-709. https://doi.org/10.1093/heapol/czx014
[11]
Nelson, E.U.E. (2024) Harm Reduction Programmes for People Who Inject Drugs in Nigeria: Challenges in Implementation and Sustainability. PolicyBrief, 20, 1-12.
[12]
Nelson, E., Akpabio, G., Essien, N. and Obot, I. (2024) Drug Problems and Treatment Services at the Community Level: Findings from a National Sample of Key Informants in Nigeria. Journal of Substance Use, 30, 850-856. https://doi.org/10.1080/14659891.2024.2403076
[13]
Guise, A., Ndimbii, J., Igonya, E.K., Owiti, F., Strathdee, S.A. and Rhodes, T. (2019) Integrated and Differentiated Methadone and HIV Care for People Who Use Drugs: A Qualitative Study in Kenya with Implications for Implementation Science. Health Policy and Planning, 34, 110-119. https://doi.org/10.1093/heapol/czz002
[14]
Wambugu, G.M. (2020) Uptake of Medically Assisted Therapy among People Who Inject Heroin in Mathare Low Income Settlements, Nairobi Count. Doctoral Dissertation, Nairobi Count.
[15]
Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B.D.L., et al. (2019) Global Patterns of Opioid Use and Dependence: Harms to Populations, Interventions, and Future Action. TheLancet, 394, 1560-1579. https://doi.org/10.1016/s0140-6736(19)32229-9
[16]
Kuria, S.W. (2021) Substance Use and Heroin Abstinence Rates among Patients Enrolled at Medically-Assisted Therapy Clinic at Mathari National Teaching and Referral Hospital. Doctoral Dissertation, University of Nairobi.
[17]
Volkow, N.D., Frieden, T.R., Hyde, P.S. and Cha, S.S. (2014) Medication-Assisted Therapies—Tackling the Opioid-Overdose Epidemic. NewEnglandJournalofMedicine, 370, 2063-2066. https://doi.org/10.1056/nejmp1402780
[18]
Omary, R.S. (2023) Incidence and Predictors of Non-Adherence and Reported Barriers of Adherence to Medication Assisted Treatment with Methadone Among Adults with Opioid Use Disorder in Dodoma, Tanzania. Master’s Thesis, University of Dodoma (Tanzania).
[19]
Krawczyk, N., Fawole, A., Yang, J. and Tofighi, B. (2021) Early Innovations in Opioid Use Disorder Treatment and Harm Reduction during the COVID-19 Pandemic: A Scoping Review. Addiction Science & Clinical Practice, 16, Article No. 68. https://doi.org/10.1186/s13722-021-00275-1
[20]
Mattick, R.P., Breen, C., Kimber, J. and Davoli, M. (2014) Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence. Cochrane Database of Systematic Reviews, 2014, CD002207. https://doi.org/10.1002/14651858.cd002207.pub4
[21]
Sordo, L., Barrio, G., Bravo, M.J., Indave, B.I., Degenhardt, L., Wiessing, L., et al. (2017) Mortality Risk during and after Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies. British Medical Journal, 357, j1550. https://doi.org/10.1136/bmj.j1550
[22]
White, K.A. (2018) Exploring the Perspectives and Experiences of Physicians in WV—Who Prescribe Medication-Assisted Treatment (MAT) to Patients with Opioid use Disorder (OUD). Theses, Marshall University.
[23]
Ayon, S., Jeneby, F., Hamid, F., Badhrus, A., Abdulrahman, T. and Mburu, G. (2019) Developing Integrated Community-Based HIV Prevention, Harm Reduction, and Sexual and Reproductive Health Services for Women Who Inject Drugs. Reproductive Health, 16, Article No. 59. https://doi.org/10.1186/s12978-019-0711-z
[24]
Volkow, N.D., Jones, E.B., Einstein, E.B. and Wargo, E.M. (2019) Prevention and Treatment of Opioid Misuse and Addiction. JAMA Psychiatry, 76, 208-216. https://doi.org/10.1001/jamapsychiatry.2018.3126
[25]
Bojko, M.J., Mazhnaya, A., Marcus, R., Makarenko, I., Islam, Z., Filippovych, S., et al. (2016) The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment. Journal of Substance Abuse Treatment, 66, 37-47. https://doi.org/10.1016/j.jsat.2016.03.003
[26]
Mlaki, D.A., Mbwambo, J.K., McCurdy, S., Masao, F.A. and Kaduri, P.A. (2022) Twelve-Month Treatment Retention and Associated Factors: A Comparison of 2 Medically Assisted Therapy Clinics in Dar Es Salaam, Tanzania. Journal of Addiction Medicine, 16, e382-e389. https://doi.org/10.1097/adm.0000000000000995
